Keros Therapeutics to Present at Key Healthcare Conferences
Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with disorders related to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) protein family. The Company has announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will be presenting at several upcoming healthcare conferences.
Participation in Significant Conferences
Keros will participate in important healthcare events where they will discuss their advancements and share insights into biopharmaceutical development. These conferences serve as vital platforms for networking and promoting groundbreaking treatments. Here are the details of their presentations:
Morgan Stanley 22nd Annual Global Healthcare Conference
Date and Time: Wednesday, September 4, 2024, at 4:05 p.m. Eastern time
Format: Fireside Chat Presentation
2024 Wells Fargo Healthcare Conference
Date and Time: Thursday, September 5, 2024, at 10:15 a.m. Eastern time
Format: Fireside Chat Presentation
2024 Cantor Global Healthcare Conference
Date and Time: Thursday, September 19, 2024, at 8:35 a.m. Eastern Time
Format: Fireside Chat Presentation
Access to Archived Presentations
For investors and those interested in Keros Therapeutics' progress, archived recordings of each presentation will be available in the Investors section of the Keros website after each event concludes. These resources are expected to remain accessible for up to 90 days, allowing attendees and stakeholders to revisit the information shared during the presentations.
About Keros Therapeutics, Inc.
Keros Therapeutics is committed to addressing a variety of medical conditions through innovative therapies. The Company focuses on the complexities of TGF-ß proteins, which are essential for numerous bodily functions, including the growth, repair, and maintenance of various tissues such as blood, bone, and muscle. Keros has shown a strong dedication to developing therapies that provide significant benefits to patients. Their leading product candidate, elritercept (KER-050), aims to treat low blood cell counts, including anemia and thrombocytopenia, particularly in patients with myelodysplastic syndromes and myelofibrosis. Additionally, they are developing cibotercept (KER-012) for pulmonary arterial hypertension, while KER-065 targets conditions related to obesity and neuromuscular diseases.
Contacting Keros Therapeutics
For any investor inquiries, Justin Frantz can be reached via email at jfrantz@kerostx.com or by phone at 617-221-6042.
Frequently Asked Questions
What is Keros Therapeutics known for?
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on creating novel therapeutics for disorders associated with TGF-ß signaling.
Which healthcare conferences will Keros participate in?
Keros will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference, the 2024 Wells Fargo Healthcare Conference, and the 2024 Cantor Global Healthcare Conference.
What is the significance of the TGF-ß protein family?
The TGF-ß protein family plays a vital role in regulating the growth, repair, and maintenance of various tissues in the body, making it an important target for therapeutic development.
What are Keros' leading product candidates?
Keros' leading product candidates include elritercept (KER-050) for treating low blood cell counts, cibotercept (KER-012) for pulmonary arterial hypertension, and KER-065 for conditions related to obesity and neuromuscular diseases.
How can investors access Keros' presentations?
Archived recordings of Keros' presentations will be available in the Investors section of their website for up to 90 days after each event.